Viatris (VTRS) Cash from Operations (2019 - 2026)
Viatris (VTRS) posted Cash from Operations of $381.8 million for Q2 2026, down 1.67% on a QoQ basis from $388.3 million in Q1 2026, and up 73.78% year-over-year from $219.7 million in Q2 2025.
Analysis
Viatris (VTRS) Cash from Operations (2019 - 2026) Analysis & Trends
Viatris has reported Cash from Operations for 8 years, with the latest figure at $381.8 million in Q2 2026.
- On a quarterly basis, Cash from Operations rose 73.78% year-over-year to $381.8 million in Q2 2026; TTM through Jun 2026 was $2.3 billion, a 12.9% increase from a year earlier, with the FY2025 full-year figure at $2.3 billion, up 0.56% from the prior year.
- Cash from Operations was $381.8 million for Q2 2026 at Viatris, down from $388.3 million in the prior quarter.
- The five-year high for Cash from Operations was $1.1 billion in Q1 2022, with the low at $189.0 million in Q4 2022.
- Average Cash from Operations over 5 years is $627.1 million, with a median of $591.6 million recorded in 2023.
- The sharpest annual moves came in 2022 and 2023: Cash from Operations plunged 63.87% in 2022, then jumped 200.79% in 2023.
- Over 5 years, Cash from Operations stood at $189.0 million in 2022, then surged by 200.79% to $568.5 million in 2023, then fell by 15.09% to $482.7 million in 2024, then jumped by 69.01% to $815.8 million in 2025, then plunged by 53.2% to $381.8 million in 2026.
- The last three Cash from Operations figures came in at $381.8 million (Q2 2026), $388.3 million (Q1 2026), and $815.8 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.34 Bn | 38.68 Bn | 2.15 Bn | 411.00 Mn |
| 2 | Viatris | 19.39 Bn | 18.50 Bn | 1.46 Bn | 381.80 Mn |
| 3 | Dr Reddys Laboratories | 9.99 Bn | 9.85 Bn | 396.53 Mn | -9.79 Mn |
| 4 | Amneal Pharmaceuticals | 5.57 Bn | 5.53 Bn | 334.51 Mn | -21.24 Mn |
| 5 | Bausch Health Companies | 2.45 Bn | 1.58 Bn | 2.10 Bn | 670.00 Mn |
| 6 | Ani Pharmaceuticals | 1.70 Bn | 1.34 Bn | 165.89 Mn | 56.67 Mn |
| 7 | Alvotech | 1.66 Bn | 1.52 Bn | 2.56 Mn | -19.79 Mn |
| 8 | Amphastar Pharmaceuticals | 985.90 Mn | 695.77 Mn | 93.47 Mn | 51.32 Mn |
| 9 | Fennec Pharmaceuticals | 434.07 Mn | 392.82 Mn | 17.15 Mn | - |
| 10 | NutriBand | 72.57 Mn | 69.15 Mn | 181,874.00 | -584,999.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 381.80 Mn |
| Mar 31, 2026 | 388.30 Mn |
| Dec 31, 2025 | 815.80 Mn |
| Sep 30, 2025 | 744.90 Mn |
| Jun 30, 2025 | 219.70 Mn |
| Mar 31, 2025 | 535.50 Mn |
| Dec 31, 2024 | 482.70 Mn |
| Sep 30, 2024 | 826.50 Mn |
| Jun 30, 2024 | 379.10 Mn |
| Mar 31, 2024 | 614.60 Mn |
| Dec 31, 2023 | 568.50 Mn |
| Sep 30, 2023 | 835.20 Mn |
| Jun 30, 2023 | 525.10 Mn |
| Mar 31, 2023 | 971.20 Mn |
| Dec 31, 2022 | 189.00 Mn |
| Sep 30, 2022 | 869.00 Mn |
| Jun 30, 2022 | 802.50 Mn |
| Mar 31, 2022 | 1.14 Bn |
| Dec 31, 2021 | 523.10 Mn |
| Sep 30, 2021 | 1.09 Bn |